The global oligonucleotide synthesis, modification, and purification services market size was accounted at US$ 1.56 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 17.50% from 2022 to 2030. Synthetic DNA oligonucleotides are applied in a wide range of applications, from fundamental research to clinical diagnostics and biotherapeutics. Oligonucleotides are chemically synthesized molecular chains from nucleosides. Solid-phase synthesis is the most popular method used for oligonucleotides chemical synthesis. They have a variety of uses in biology, biochemistry, molecular diagnostics, genomics, forensics, and others. Selecting the suitable oligonucleotide synthesizer for application is critical to optimizing product quality while maintaining cost-effectiveness.
The primary elements boosting the growth of the oligonucleotide synthesis, modification, and purification services market include increasing demand for oligonucleotides, growing preference of patients toward personalized medicines, rising collaborations and mergers/acquisitions by manufacturers, and growing older population, and the high prevalence of chronic diseases. Apart from this, the need for high-quality oligos is increasing due to the increase in R&D activities. Therefore, biotech and pharmaceutical companies' increasing research and development activities to treat various viral infections, chronic diseases, and genetic disorders are expected to fuel market growth over the forecast years. For instance, in July 2017, Nitto Denko Avecia Inc. (Avecia) opened a new oligonucleotide API manufacturing facility in Milford, MA. The expansion has added 20,000 sq. ft. of manufacturing and office space at the site and provided CGMP oligonucleotide manufacturing capacity up to 1.8 mol, bringing the site capacity to 3.0 mol. Also, this expansion has helped Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials. However, the low-quality oligonucleotide sequences, lack of technical requirements, and the complexities associated with the oligonucleotide synthesis may hamper the market growth.
The oligonucleotide synthesis, modification, and purification services market is classified based on oligonucleotide mfg. Types, applications, operation scale, therapeutic areas, end-users, and region. By oligonucleotide mfg. Types, the market comprises antisense oligonucleotides, siRNA, miRNA, and other oligonucleotides. The antisense oligonucleotides segment is anticipated to hold the highest market share over the forecast period owing to the increasing demand for oligonucleotides. The market is grouped into research and diagnostic, therapeutic, and contract manufacturing (OEM) in terms of applications. The research and diagnostic segment are expected to dominate this market in the near future due to the increasing novel diagnostic and therapeutic applications for oligos. The operation scale segment is divided into large-scale oligonucleotide synthesis, intermediate-scale oligonucleotide synthesis, and small-scale oligonucleotide synthesis. By therapeutic areas, the market is segmented into oncological disorders, eye disorders, metabolic disorders, autoimmune disorders, and other therapeutic areas. The oncological disorders would be the fastest-growing segment of this market in the coming days owing to the rising incidence of Cancer and the rising geriatric population. By end-users, the market is classified into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, Contract research organizations (CROs) and contract manufacturing organizations (CMOs), and academic research institutes. The market is being examined throughout North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Due to increased R&D investments in pharma and biotech businesses to enhance oligonucleotide production and synthesis processes, North America is likely to have the largest share of this market throughout the forecast years, followed by Europe.
Some of the essential players operating in the oligonucleotide synthesis, modification, and purification services market are Ajinomoto Bio-Pharma Services, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, MilliporeSigma, BioSpring, CordenPharma, Nitto Denko Avecia, TriLink Biotechnologies, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., GE Healthcare, GeneDesign, Inc., Bio-synthesis Inc., ATDBio Ltd, Burkert UK Limited, Almac Group, and Other Prominent Players.
Companies Mentioned
- Ajinomoto Bio-Pharma Services
- Integrated DNA Technologies
- Kaneka Eurogentec
- LGC Biosearch Technologies
- Microsynth
- MilliporeSigma
- BioSpring
- CordenPharma
- Nitto Denko Avecia
- TriLink Biotechnologies
- Eurofins Scientific SE
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- GE Healthcare
- GeneDesign, Inc.
- Bio-synthesis Inc.
- ATDBio Ltd
- Burkert UK Limited
- Almac Group
Other Prominent Players
Global Oligonucleotide Synthesis, Modification, and Purification Services Market, by Applications, 2020-2030 (Value US$ Mn)
